Publications

Search our bibliography using the filters on the right-hand side.

Displaying 101 through 150 of 157 publications.

Arana A, Wentworth CE, Ayuso-Mateos JL. Suicidality in patients treated with AEDs. Presented at the 25th International Conference on Pharmacoepidemiology; 2009.

Arana A, Allen S, Burkowitz J. Evaluation of the infliximab (Remicade®) pediatric crohn's disease educational plan. Presented at the 25th International Conference on Pharmacoepidemiology; 2009.

Arana A. Safety surveillance plans: strategies for monitoring safety during the development. Presented at the 21st Annual EuroMeeting of the Drug Information Association; 2009.

Arellano FM, Arana A, Wentworth CE, Fernández-Vidaurre C C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol Pract. 2009;123(5):111-6-116.

Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Arana A, Rothman KJ. Use of Cyclo-Oxygenase 2 Inhibitors (COX-2) and prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in UK and USA populations. Pharmacoepidemiol Drug Saf. 2008 Oct 1;17(10):1037. doi: 10.1002/pds.1636

Arana A, Arellano FM, Rivero E, Pavesi M, Dey D, Wentworth CW. Intravitreal (IVT) injection-related ocular adverse events in the general population of the United States of America. Poster presented at the 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2008. Copenhagen, Denmark. [abstract] Pharmacoepidemiol Drug Saf. 2008 Aug; 17(Suppl 1):S75-6.

Wentworth CW, Arellano FM, Rivero E, Pavesi M, Dey D, Arana A. Use of intravitreal (IVT) injection therapies in the general population of the United States of America. Presented at the 24th International Conference on Pharmacoepidemiology; August 2008. Copenhagen, Denmark. [abstract] Pharmacoepidemiol Drug Saf. 2008 Aug; 17(Suppl 1):S251-2.

Arana A, Arellano FM, Rivero E, Parvesi M, Dey D, Wentworth CE. Intravitreal (IVT) injectionrelated ocular adverse events in the general population of the United States of America. Presented at the 24th International Conference on Pharmacoepidemiology; 2008.

Arellano FM, Arana A, Wentworth CE. Occurrence of lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. Presented at the 24th International Conference on Pharmacoepidemiology; 2008.

Conde E, Arellano FM, Wentworth CE, Schlienger R, Fernández-Vidaurre C, Arana A. Validation of cases of lymphoma in THIN. Presented at the 24th International Conference on Pharmacoepidemiology; 2008.

Arana A, Wentworth CE, Conde E. Cancer incidence in patients with and without atopic dermatitis in the United Kingdom. Presented at the 23rd International Conference on Pharmacoepidemiology; 2007.

Arana A, Arellano FM, Wentworth CE. Cancer incidence in patients with and without atopic dermatitis in the United Kingdom. Presented at the Annual Meeting of the Society for Investigative Dermatology; 2007. Previously presented at the 23rd International Conference on Pharmacoepidemiology.

Arana A, Arellano FM. Cancer incidence near oilfields in the Amazon basin of Ecuador revisited. Occup Environ Med. 2007;64(7):490.

Arellano FM, Wentworth CE, Conde E, Schlienger R, Fernández-Vidaurre C, Arana A. Incidencia de cáncer en pacientes con y sin atópica dermatitis en Inglaterra. Presented at the VII Jornadas de Farmacovigilancia; 2007.

Arellano FM, Arana A, Wentworth CE. Risk of lymphoma among users of topical corticosteroids and topical calcineurin inhibitors. Presented at the Annual Meeting of the Society for Investigative Dermatology; 2007.

Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4):808-16.

Arana A, Varas C, Gonzalez-Perez A, Gutierrez L, Bjerrum L, Garcia Rodriguez LA. Hormonal therapy and cerebrovascular events: a population-based nested case-control study. Menopause. 2006 Sep 1;13(5):730-6.

Sanchez Matienzo D, Lanza LL, McQuay L, Gutierrez L, Arana Navarro A, Perez-Gutthann S. Descriptive study of users of depo-medroxyprogesterone acetate (DMPA) in the mhra gprd. Presented at the 22nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2006. Lisbon, Portugal.

Arellano FM, Wentworth CE, Arana A. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. Presented at the 22nd International Conference on Pharmacoepidemiology; August 2006. Lisbon, Portugal.

Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther. 2006 Aug 1;28(8):1123-32.

Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in users of NSAIDs, including COX-2 selective inhibitors. A case/non-case analysis of spontaneous reports. Clin Ther. 2006;28(8):1123-32.

Arana A, Rivero E, Egberts TCG. What do we show and who does so? An analysis of the abstracts presented at the 19th ICPE. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):s330-1.

Arana A, Arellano FM, Sánchez-Matienzo D, Perez-Gutthann S. Choosing the measure of relative proportional reporting in quantitative analyses of spontaneous reports. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S324.

Maguire A, Arellano Felix M, Perez-Gutthann S, Arana A. Risk benefit modeling: the use of stochastic simulation for safety evaluations. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S272.

Sanchez-Matienzo D, Castellsague J, Arana A. Effect of control of confounding in the estimation of the proportional reporting ratio. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S225-6.

Leufkens HG, Arana A. Pharmacoepidemiology adds to orphan drug development. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S256-7.

Arana A, Castellsague J, Trave F, Perez-Gutthann S, Rothman KJ, Arellano FM. Early estimation of excess risk of serious cutaneous reactions for newly marketed drugs. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):165.

Arana A, Broeckmans AW. Validity of epidemiological research conducted following Good Clinical Practice Guidelines. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.

Tuells A, Arana A, Perez-Gutthann S, García-Rodríguez LA. El Proyecto BIFAP. Inv Clin Farm. 2003;0:25-6.

Sánchez Matienzo D, Gimeno V, Castellsague J, Arana A. Safety profile of smell and taste disorders in patients treated with cox-2 specific inhibitors and other selected drugs. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.

Sánchez Matienzo D, Gimeno V, Castellsague J, Arana A. A comparative safety profile of serious skin and hypersensitivity reactions: cOX-s specific inhibitors vs. non-selective NSAIDs and other selected drugs. Presented at the 19th International Conference on Pharmacoepidemiology; 2003. [abstract] Pharmacoepidemiol Drug Saf. 2003; 12(S1):S185.

Sánchez Matienzo D, Gemino V, Castellsague J, Arana A. Safety profile analysis of liver disorders in patients treated with celecoxib and rofecoxib. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.

Arana A, Cid Ruzafa J, Rueda de Castro AM, Warner BA, O'Sullivan D. Evaluation of the clozaril® patient monitoring service (CPMS) in the prevention of clozaril/leponex-induced white-blood-celltoxicity. Presented at the 18th International Conference on Pharmacoepidemiology; August 2002.

Cid Ruzafa J, Arana A, Rueda de Castro AM, Warner BA, Kumar V, O'Sullivan D. Effective prevention of clozaril granulocyte toxicity. Presented at the XII World Congress of Psychiatry; March 2002.

Ward A, Caro JJ, Green T, Huybrechts K, Arana A, Wait S, Eleftheriou A. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol. 2002;2(3).

Caro JJ, Ward A, Craig T, Huybrecht K, Arana A, Wait S, Eleftheriou A. Impact of thalassemia major on patients and their families. Acta Haematol. 2002;107(3):150-7.

Arana A, Gutierrez L, Garcia-Rodriguez LA, Perez-Gutthann S. Antiepileptics and liver, testes, cervix uteri and vulvar cancer: a cohort study. Poster presented at the 17th International Conference on Pharmacoepidemiology; August 2001. Toronto, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2001 Aug; 10(supp 1):128.

Arboretti R, Tognoni G, Alberti D, Arana A. Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol. 2001;56(12):915-22.

Arana JI, Jarén C, Arana A, Arazuri S. Detección de nectarinas lanosas mediante impacto no destructivo. Presented at the 1º Congreso Nacional de Ingeniería para la agricultura y el medio rural; 2001.

Arana JI, Jarén C, Arana A, Arazuri S. Pruebas diagnósticas en la clasificación de productos agrícolas. Horticultura. 2001;19:20-6.

Arana A, Wait S, Santamas M, Ward A, Huybrechts K, Craig T. Thalassemia major: geographical variations in prevalence, survival and treatment patterns. Poster presented at the 16th International Conference on Pharmacoepidemiology; August 2000. [abstract] Pharmacoepidemiol Drug Saf. 9(S1):S96.

Arana A, Bjerrum L, Roberts W. Specific congenital malformations in the offspring of women with epilepsy treated with antiepileptic drugs: a meta-analysis. Presented at the 16th International Conference on Pharmacoepidemiology; August 2000.

Arana A, Bjerrum L, Roberts W. Teratogenic effects of antiepileptic drugs: the extent and the impact of duplicate publications. Presented at the 16th International Conference on Pharmacoepidemiology; August 2000.

Pladevall M, Arana A, Varas-Lorenzo C. Systematic reviews and meta-analyses in ischemic cardiopathy. Cardiovasc Risk Fact. 2000;4:270-81.

Pladevall-Vila M, Arana A, Varas-Lorenzo C. Systematic reviews and meta-analysis on coronary heart disease. (Revisiones sistemáticas y meta-análisis en cardiopatía isquemica). Cardiovasc Risk Fact. 2000;4:270-81.

Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry. 1999 Dec;175:575-80. doi: 10.1192/bjp.175.6.576

Arana A. A North American Registry for epilepsy and pregnancy, a unique public/private partnership of health surveillance. Epilepsia. 1998 Jul;39(7):793-8.

Arana A, Castellsague J, Tognoni G, Perez-Gutthann S. Individual daily questionnaires in pharmacoepidemiologic studies and ways of analyzing recurrent events. Comparing tolerability of Desferal® in a real-life setting. Presented at the 13th International Conference on Pharmacoepidemiology; 1997. Orlando, FL. [abstract] Pharmacoepidemiol Drug Saf. 1997 Aug; 6(S2).

Arboretti R, Marachetti F, Carinci F, Alberti D, Arana A, Tognoni G. Evaluation of care and life of patients with beta-thalassaemia major. Presented at the 6th International Conference on Thalassaemia and the Heamoglobinopathies; 1997. Malta.

Arana A, Piero P. Validity of a quick method to identify e. coli and proteae in urine samples. Med Clin (Barc). 1994 Jan;693. doi: 10.1016/j.ahj.2013.12.006